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2 Introduction
2.1 Cancer
Cancer summarizes several heterogenous diseases which are characterized by a rapid and
abnormal cell growth with the potential to invade neighboring tissues and to spread through
the blood and lymphatic system to other organs. It comprises various molecular and cel-
lular subtypes and can affect almost every part of the body. Although some cancer types
have high cure rates by now, if they are diagnosed early and treated according to best
current practice, cancer is the second leading cause of death worldwide with 8.8 million
deaths in 20151. Lung, liver, colorectal, stomach and breast cancer cause most cancer
deaths and the American Cancer Society expects that 600,920 Americans will die of can-
cer in 2017, which are about 1,650 people daily2. The Word Health Organization (WHO)
assumes an increase of 70% in the number of new cancer cases over the next 20 years1.
Thus, there is an urgent demand for the development of new anticancer drugs and therapy
strategies. Besides surgery, radiotherapy and conventional chemotherapy, the concept of
immunotherapy by oncolytic viruses (OV) and the targeted therapy by receptor tyrosine
kinase inhibitors (TKIs) are offering new treatment options to cure or considerably prolong
life of patients.
2.2 Oncolytic viruses
Oncolytic viruses are replication-competent viruses with the ability to specifically infect
and kill tumor cells whilst healthy cells are spared. Two types of OV are known: i) naturally-
occurring animal-hosted viruses with innate tumor lysis capacities and no or only weak
human pathogenicity and ii) genetically engineered oncolytic viruses which are virulent to
tumor cells only but cannot replicate in normal human cells3,4. OVs exploit exactly those
tumor-specific alterations which promote abnormal cell growth and thus lead to tumor cell
necrosis or apoptosis. Thereby, cancer cells serve as endogenous bioreactors for virus repli-
cation and the release of new virus particles leads to an infection of surrounding tumor
cells resulting in a continuous process of repeated tumor infection, cell death and virus re-
lease3–5 (figure 2.1). Thus, an increase in virus exposure offers the potential of low initial
OV doses. However, the tumor cell lysis eventuates in a self-limitation of OV production
due to a decreased availability of bioreactors for further virus amplification.
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Figure 2.1 Schematic representation of oncolytic virus infection of normal and tumor cells. Whilst the antiviral
defense in normal cells prevents a virus replication and cells will survive undamaged, tumor cells
fail to suppress virus replication. This leads to tumor cell lysis and release of progeny virus particles
which infect neighboring tumor cells and amplify the virus infection.
Several oncolytic viruses have already entered clinical trials6 and in 2015 the genetically
engineered herpes virus Imlygic® (talimogene lapharevec) was approved in the USA and
Europe for the treatment of advanced melanoma7,8. For the naturally oncolytic viruses
Newcastle disease virus (NDV), reovirus (RV) and parvovirus (PV) strong oncolytic capac-
ities against glioma have been described in vitro and in vivo4,9.
NDV is an enveloped single-stranded RNA virus of 150-300 nm size and the lentogenic
NDV strain Hitcher B1 causes mild respiratory diseases in chicken and turkeys. Since
virus replication depends on the deficient interferone signaling pathway in tumor cells,
in healthy human cells interferon-induced antiviral proteins block the production of viral
components at different levels of the viral replication cycle10,11.
RV is a non-enveloped virus with double-stranded RNA genome and forms particles with
a size of 60-90 nm. Its name, which is an acronym of "respiratory enteric orphan", indicates
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that a RV infection is manifested by respiratory and gastrointestinal diseases but the course
of the infection is in most cases asymptomatic. The type III dearing stream is under clinical
development and its replication dependents on ras-mediated signaling transduction which
is activated in most human cancers6,12.
The non-enveloped PV is a single-stranded DNA virus and induces cell death mainly due
to apoptosis13, whereby its oncolytic activity seems to depend on the loss of genetic stabil-
ity in cancer cells14. Parvoviruses are with only 20-25 nm the smallest existing viruses.
The lifecycle of OVs is influenced by their ability to self-replicate, the availability of tumor
cells for virus production but also by the host immune system which on the one hand may
foster the antitumoral effect but also limits the ongoing virus replication and spread6,15.
Thus, OVs have unique pharmacokinetic properties which need to be understood and
quantified for a successful translation of OVs from the culture dish to preclinical models
and finally to the clinic.
2.3 Small molecule tyrosine kinase inhibitors
The era of targeted therapy started with the development of the Bcr-Abl tyrosine kinase
inhibitor Imatinib for the treatment of chronic myelogenous leukemia16,17. By now, about
90 human tyrosin kinases (TK) are known, which are involved in the regulation of multi-
ple processes such as cellular proliferation, differentiation and survival18. Abnormal TK
functions are associated with the development and progression of cancer and thus a major
focus in cancer research has been on the development of several TK inhibitors18,19.
Increasingly attention has been paid to the insulin-like growth factor 1 receptor (IGF1R),
a receptor tyrosine kinase which was found to play a key role in oncogenic transforma-
tion and tumorgenesis20–22. Binding of the natural ligands insulin-like growth factor (IGF)
1 and 2 to the extracellular domain results in receptor autophosphorylation (pIGF1R) and
activation of mitogenic and anti-apoptotic downstream cascades23. IGF1R is structurally
and functionally related to the insulin receptor (INSR) isoforms INSRA and INSRB23. While
INSRA is mainly expressed in tumor cells and binds IGF2 and insulin to foster tumor cell
proliferation and survival, INSRB is responsible for glucose uptake in metabolic tissue such
as skeletal muscle, hepatocytes and adipocytes. Anticancer strategies to block the IGF
signaling system comprise antibodies against the ligands IGF 1 and 224, IGF1R antibod-
ies25 and dual IGF1R/INSR tyrosine kinase inhibitors26–28. Since INSR can compensate for
IGF1R to stimulate tumor cell growth29,30 IGF1R antibody mediated efficacy is limited and
4
2.4 Obstacles in cancer drug development
clinical trials with IGF1R antibodies were discouraging31,32. Thus a dual IGF1R/INSR in-
hibition by small molecule TKIs may lead to an increased anti-tumor efficacy33 and indeed,
some IGF1R/INSR TKIs have been already investigated in clinical trials34. However, tran-
sient hyperglycemia due to INSRB inhibition has been reported as a relevant safety issue in
animals and humans26,35,36 (figure 2.2) and needs to be addressed appropriately.
Figure 2.2 Schematic representation of the IGF1R and INSR signaling pathway in tumor and metabolic cells. In
the absence of a TKI an IGF1R and INSR-A activation by IGF1, IGF2 or insulin results in cell growth
and survival stimulation in tumor cells. In metabolic cells the insulin mediated activation of INSR-B
induces the translocation of the GLUT4 transporter to the cell surface to enable glucose uptake into
the cell. While in tumor cells the binding of the TKI at the intracellular domain of IGF1R and INSR-A
results in cell cycle arrest and apoptosis, the TKI mediated inhibition of INSR-B in metabolic cells
hampers the glucose uptake and evokes transient hyperglycemia.
BI 893923 is a novel potent and selective IGF1R/INSR tyrosine kinase receptor inhibitor
with a molecular weight of 501 g/mol, beneficial drug-like properties and good tolerability
in the mouse model. For a safe and effective use of BI 893923 as new anti-cancer therapeutic
in humans, a dose selection based on a quantitative assessment of the anti-tumor efficacy
against the risk of hyperglycemia will be essential.
2.4 Obstacles in cancer drug development
Despite these exciting and promising new approaches to target tumor cells by oncolytic
viruses or IGF1R/INSR TKIs, the translation of preclinical findings to the clinic is still diffi-
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cult with a clinical success rate in the development of new anti-cancer drugs of only 5%37.
Major causes for the attrition are a lack of efficacy and safety accounting for about 60% of
failures37. Already the successful translation of in vitro compound potency to the in vivo
setting is hampered due to the artificial nature of cultured cell lines and because they are
grown for many generations failing to reveal the natural state of the tumor38. Further, cul-
tured cells fail to embrace the complete genetic tumor heterogeneity and cannot represent
the complex cellular and architectural nature of tumors comprising of stroma, blood vessels
and immunocompetent cells38. Although xenograft models consist of stroma components,
this is not of human nature and furthermore, the environment and interaction between a
subcutaneous tumor and the host is different compared to the tumor in its original tissue.
Essential genetic, molecular, immunologic and cellular differences between mice and men
may lead to translational limitations and the complex processes of human carcinogenesis,
physiology and progression are inadequately reflected by animal models39,40. Especially
pharmacokinetic differences between human and mouse are leading to a failure of safety
and efficacy translation from animal studies to clinical testing41.
2.5 Pharmacometric modeling in cancer drug development
To overcome drug development failures due to safety issues and lack of efficacy and to
foster the successful translation of preclinical findings to human, the main objective is
to improve the transferability of pharmacokinetics (PK) and pharmacodynamics (PD) be-
tween species. This can be realized by pharmacometric modeling41,42, which is based upon
a comprehensive understanding of the disease and therapeutic approach by considering
the mechanism of drug action. It mechanistically characterizes the relationship between
the administered dose, drug concentration in plasma and biophase (PK) and further the
biomarker modulation as well as drug effects and side-effects (PD). Thus, pharmacometric
modeling incorporates data on drug properties, the target, pathway modulation as well as
pharmacology and safety43. Accounting for species differences, translational pharmaco-
metric modeling allows an extrapolation of the pharmacological response to human based
on the exposure-response relationship in animals44. The Food and Drug Administration
(FDA) explicitly suggests the utilization of model-based drug development by pharmaco-
metric analysis since translational pharmacometric modeling allows an improved clinical
trial design, supports the optimization of the dosing regimen, decreases the number of
animal studies and thus reduces overall costs43,45. From 2000 to 2008 the number of sub-
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missions where pharmacometric modeling was applied increased by 6-fold, whereof 13%
of submissions were in the therapeutic area of oncology46. In more than 60% of submis-
sions where pharmacometric analyses were utilized, they influenced drug approval and
labeling decisions and in those submissions where pharmacometric modeling contributed
to drug approval decision, about 50% of reviews provided pivotal or supportive insights
into effectiveness and safety46. Meanwhile, pharmacometric analyses play a central role
in regulatory decision making by improving drug development knowledge management.
Thus, pharmacometric modeling can serve as a valuable tool to foster the translation of the
new anticancer concepts of oncolytic viruses and the TKI BI 893923 to the clinic.
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3 Aims of this thesis
The main objective of this thesis was to foster the development of new anti-cancer drugs by
supporting the translation at the preclinical-clinical interphase via pharmacometric model-
ing exemplarily at the concepts of oncolytic viruses and the TKI BI 893923.
Due to the exceptional pharmacokinetic features of oncolytic viruses, an encompassing un-
derstanding of the complex relation between tumor growth and virus replication is indis-
pensable to characterize the efficacy of a certain oncolytic virus and to identify optimal
dosing regimens. Hence, the aim of the first part of this theses was to develop a generic vi-
ral dynamic model to describe the bidirectional interaction between tumor growth of U87
glioblastoma cells and the viral dynamics of the three different oncolytic viruses NDV, RV
and PV in an in vitro setting. It was further aimed to apply the established model for virus
potency characterizations and for simulations of different dosing scenarios for an extended
period of time to identify the optimal dosing scheme for follow up studies.
As the dual inhibition of IGF1R/INSR by the selective TKI BI 893923 is another encouraging
new treatment approach, the potential dose-limiting metabolic intolerabilities due to tran-
sient hyperglycemia needs to be addressed appropriately. Thus, for a successful transition
to clinic a comprehensive understanding of the relationship between BI 893923 plasma con-
centration and the desired effect of IGF1R blockade with resulting tumor growth inhibition
as well as the undesired effect of hyperglycemia will be crucial to maximize the therapeutic
window of this agent. Hence, in the second part of the thesis it was aimed to develop a
population PK/PD model for the novel TKI BI 893923 to describe its plasma concentration,
pIGF1R biomarker modulation and resulting tumor growth inhibition as well as blood glu-
cose levels in mice. The established model should be used for dose adjustment simulations
in mice to counterbalance tumor growth inhibition versus the risk of hyperglycemia.
In the third part of this thesis it was aimed to translate the developed mouse PK/PD for
BI 893923 to human by allometric scaling of PK and blood glucose, as surrogate PD end-
point, using data from mouse, rat, dog, minipig and monkey. In addition, it was intended
to conduct a comprehensive risk-benefit analysis for humans to balance anti-tumor effi-
cacy and metabolic toxicity in order to support the human therapeutic dose estimation by
a rational recommendation of an optimal efficacious dosing scheme.
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4.1 Pharmacometric drug-disease modeling
4.1.1 Background
Pharmacometics describes the development and application of mathematical and statistical
models to characterize, understand and predict a drugs PK and PD. Thus, it supports ratio-
nal, data-driven decisions in drug development, regulatory approval and pharmacother-
apy. Pharmacokinetics describes the fate of a drug in the body and characterizes the rela-
tionship between the administered drug and drug concentration by absorption, distribu-
tion, metabolism and elimination processes. The plasma concentration-time profile can be
depicted by compartmental PK modeling where the body is divided in several pharmacoki-
netically distinct compartments which correspond to the number of distribution phases47.
The pharmacological effect of a drug on the body can be described by pharmacodynam-
ics48. It characterizes the relationship between the drug concentration and the pharmaco-
logical effects and the relationship of those responses to clinical outcomes. PD markers can
be biomarker measurements (e.g. level of receptor activation) or efficacy and toxicity out-
comes such as tumor growth inhibition or level of hyperglycemia, respectively. The drug
effect in dependency of the drug concentration can be described by various well-established
PD models such as simple linear models or the often applied Emax-Model49.
PK/PD modeling describes the drug exposure and drug effect over time and enables the
assessment of desired and undesired drug effects in dependency of drug exposure. It helps
to understand the dose-exposure-effect relationship to support preclinical and clinical drug
development as well as dose finding for a safe and efficacious use.
4.1.2 The population approach
To describe the PK and PD of a drug, every individual can be analyzed separately using the
individual compartmental analysis (ICA). However, more complex processes might not be
identified in single individuals and generalized statements about a population of individ-
uals can be more reliably derived using the population approach. This method describes
the typical PK and PD profile of a population and quantifies the variability within this
population50. Large datasets from different experiments and studies can be combined and
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analyzed together whereby the experiment design can vary with respect to sampling time
and number of observations. Three different population approaches can be distinguished:
• The naïve pooled analysis combines data from all individuals and estimates the typi-
cal model parameters, whilst variability between individuals is not considered51.
• The standard two-stage approach estimates in the first step model parameters for
each individual separately using the ICA and calculates in the second step the mean
and percentiles to quantify the variability between individuals52. With this approach
the source of variability cannot be identified, leading to a systematic overestimation
of variability within the population since the calculated variability represents both
interindividual and residual variability53. Further, a complete plasma concentration-
time profile for each individual is needed (data-rich situation) and a balanced study
design is necessary.
• In nonlinear mixed-effects (NLME) modeling all individual measurements are ana-
lyzed simultaneously and the typical PK and PD profiles as well as the variability
within a population are described. PK and PD variability within a population can
be adequately quantified and distinguished in interindividual, interoccasional and
residual variability51,52. Further, individual specific characteristics (covariates) such
as body weight can be considered and quantitatively related to certain model pa-
rameters to explain and reduce variability. This method can be used for unbalanced
study designs due to pooled experiments and in data-sparse situations when few or
only one measurement per individual is available, for instance when animals had to
be scarified for determination of biomarker levels. Due to the superiority of NLME
modeling, this approach was applied in this thesis and will be described in detail in
the following section.
4.1.3 Nonlinear mixed-eﬀects modeling
The NLME modeling approach denotes a particular kind of nonlinear regression analysis
in which the observed data (plasma drug concentrations or PD readouts) are described by
a mathematical function (model) which is a nonlinear combination of the model parame-
ters54. The term "mixed-effects" results from the simultaneous estimation of "fixed effects",
representing population parameters and covariate effects and "random effects", accounting
for unexplainable intra- and interindividual variability as well as residual variability55.
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A NLME-model consists of three hierarchical components: i) the structural model describ-
ing the typical PK or PD profile for the population, ii) the statistical model, which quanti-
fies the unexplained variability within this population and iii) an optional covariate model,
which explains part of the variability by individual-specific characteristics (covariates). A
general expression of a NLME model is shown in equation 4.1:
Y = f (θ, x, z,Ω,K,Σ) (4.1)
The observations Y are described by the function f (), which determines the mathematical
structure of the model and contains θ, which is the vector of the typical population param-
eters. x denotes the vector of the independent design parameters (e.g. dose, time) and z
the optional vector of individual-specific covariates. The random variability parameters
are defined by the matrices Ω, K and Σ which represent the interindividual, interoccasional
and residual variability, respectively.
4.1.3.1 Structural model
The structural model describes the typical PK or PD profile at a given time as function
of model parameters and should reflect the general tendency of the observations. It is
developed in a sequential manner, starting with the simplest model and proceeding to more
complex ones by including additional parameters to capture all essential system features.
PK/PD models are developed in a step-wise process by first defining a final PK model and
then generating the PD model.
4.1.3.2 Pharmacostatistical model
The statistical model describes the variability of a structural parameter θk within a popu-
lation due to random effects and allows the estimation of individual parameters e.g. indi-
vidual clearance CL for an individual i. The variability quantified in the statistical model
may result from differences between various individuals (interindividual variability, IIV)
or from variations within one individual at different occasions (interoccasional variabil-
ity, IOV), which will not be further explained as it was not analyzed within this work.
The remaining discrepancy between the observations and model predictions is defined as
unexplainable residual variability (RUV), which may result from analytical errors, model
misspecifications or other factors.
Interindividual variability To account for the fact that parameters in a population are
often log-normal (right-skewed) distributed and to prevent the occurrence of negative and
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thus non-physiological parameter estimates the IIV is often modeled as an exponential re-
lationship:
Pki = θk · eηki (4.2)
where Pki is the individual structural parameter and ηki the difference between the natural
logarithm of Pki and the typical population value θk. It is assumed that ηki is independently,
symmetrically distributed with zero mean and a variance ω2k . The variance represents the
diagonal element of the variance-covariance-matrix Ω and can be reported as coefficient of
variation (CV) which is calculated as:
CV[%] =
√
eω
2
k − 1 · 100% (4.3)
Although, in theory variability is plausible for every parameter, a dataset does not always
contain sufficient information for a reliable quantification of the variability. Thus, the deci-
sion to include the IIV was based on the objective function value (OFV, section 4.1.5.1), the
precision and the relevance of the estimated value itself.
Residual variability The remaining deviation between individual model predictions
and observations is considered as random and was investigated by the following three
implementations to describe the RUV.
• Additive error model:
yij = f (φi,Xij) + εadd,ij (4.4)
• Proportional error model:
yij = f (φi,Xij) · (1+ εprop,ij) (4.5)
• Combined error model:
yij = f (φi,Xij) · (1+ εprop,ij) + εadd,ij (4.6)
yij is the measured observation of the i-th individual at time j, f (φi,Xij) represents the in-
dividual model prediction and εadd,ij and εprop,ij quantify the random difference between
yij and f (φi,Xij). It is assumed that ε ij is distributed symmetrically with mean zero and
a variance σ2, which represents the diagonal element of the Σ matrix. The additive error
model assumes that the variance is constant over the whole range of observations, which
12
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is often the case for measurements with narrow range such as PD readouts. The standard
deviation of the additive residual variability is given by
√
σ2add and has the same unit as the
observation. The proportional error model is applied if the variance is dependent on the
magnitude of the observations and proportionally increases with higher values, as this is
typically the case for drug concentration.
√
σ2prop · 100 represents the coefficient of variation
of the proportional residual error in %. The combined error model merges the additive and
proportional error model. Thus, for small observations the additive residual variability
component dominates and for higher values this error model will behave like a propor-
tional error model. The final RUV model was selected based on plausibility and criteria for
model selection (section 4.1.5).
4.1.3.3 Covariate model
The covariate model describes the impact of certain individual-specific characteristics on
PK and PD parameters with the aim to explain and reduce the IIV. These variables can be
continuous such as body weight or creatinine clearance and integrated in the model as a lin-
ear, exponential or power function47. Covariates can further be categorical (dichotomous
or classified) such as sex or age range and enter the model in an additive, fractional or ex-
ponential way. Covariate integration was investigated based on plausibility and graphical
screening and decided by the OFV (section 4.1.5.1) and precision.
4.1.4 Estimation methods
In population modeling it is aimed to identify the set of model parameters, which best de-
scribes the observed data. There are several software packages available to estimate NLME
models, one of them is NONMEM® 56, which was used within this thesis. The algorithm
implemented in NOMNEM® iteratively searches for the set of parameters that maximize
the probability that the observations were adequately reproduced. Instead of maximiz-
ing the likelihood-function, NONMEM® iteratively seeks for the global minimum of minus
two times the logarithm of the likelihood−2LL, which is called the objective function value
(OFV). To approximate the function −2LL, the method of extended least square objective
function OFELS 57 is used (equation 4.7).
OFELS =
n
∑
i=1
[
(yi − E(yi))2
var(yi)
+ ln |var(yi)|
]
(4.7)
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Assuming an additive residual error model, yi represents the vector of observations and
E(yi) the vector of model prediction for yi. var(yi) is the variance-covariance matrix for yi,
which includes all variability parameter and weights the squared residual error (yi − E(yi))2.
For an infinite number of variance parameters the OFELS could become infinitely small,
which is prevented by a penalty term for every additional variance ln |var(yi)|51. Due to
the nonlinear relation between observations and parameter estimates there is no closed-
form solution for the OFELS and the minimum cannot be calculated analytically. To over-
come this issue, a Taylor series approximation can be applied to determine the minimal
OFV. Within this work two general methods implemented in NONMEM® were used: the
first order approximation (FO) and first-order conditional estimation (FOCE) method57. To
approximate the solution of the function in both methods the model function is linearized
into a first-order polynomial of the first partial derivative of the function and the func-
tion itself with respect to the random variables η and ε. For the FO method the Taylor
series approximation is solved by several iterative steps under the assumption of η = 0,
considering only the population parameters. The individual parameter estimates (condi-
tional estimates) are then assessed a posteriori using the Bayesian estimation method58. In
contrast, for the FOCE method the iterative solutions for θ and η are estimated at every iter-
ation step simultaneously and thus the population estimates and the respective individual
parameters (conditional estimates) are obtained in parallel to every iteration step and are
not estimated a posteriori. The FOCE method can be refined by the INTERACTION option
(FOCE+I), which considers a correlation between the residual and interindividual variabil-
ity. Since the interaction option can be neglected only for additive residual error models,
this option was applied for all modeling analysis within this work. In general, for model
development within this thesis the FO method was used since it converges considerably
faster and final models were estimated with FOCE+I, as this method provides more precise
parameter estimates59. Besides the deterministic FO and FOCE method other estimation al-
gorithms are available in NONMEM, which are the Laplacian Approximation (LAPLACE)
or stochastic Monte Carlo expectation-maximization (EM) methods such as Monte-Carlo
importance sampling (IMP), IMP assisted by mode a posteriori estimation (IMPMAP) or
the stochastic approximation expectation maximization (SAEM) method, which are more
valuable for more complex PK/PD models.
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4.1.5 Model selection and evaluation
To assess a models descriptive and predictive performance and to compare different kinds
of models several numerical and graphical tools can be applied.
4.1.5.1 Objective function value and Akaike information criterion
To test for a statistical significant model improvement during model building, the likeli-
hood ratio test can be applied, if models are nested. Models are denoted as nested when the
complex model can be reduced to a simpler model by omitting one or more parameters47.
The OFVs for both models are compared whereby the difference in the OFV is approxi-
mately χ2-distributed47. Thus, for one additional parameter (degree of freedom (df)=1) the
difference in the OFV has to be at least 3.84 points to be statistical significant at a given level
of significance of 0.05. To numerically compare non-nested models the Akaike Information
Criterion (AIC)47 can be applied, which uses a penalty term for every additional parameter
P. The AIC can be calculated as
AIC = −2 · LL+ 2 · P (4.8)
4.1.5.2 Relative standard error
The relative standard error (RSE) can be used to assess the precision of parameter estimates,
where a smaller RSE is associated with a higher precision. During the covariance step
NONMEM® estimates the absolute standard error of parameters from the square route of
the diagonal elements of the variance-covariance matrix. The RSE is then calculated from
the absolute standard error as follows
RSE =
absolute standard error
parameter estimate
· 100% (4.9)
Another method to determine the RSE is the bootstrap method60. For this method a suf-
ficient high number of new datasets with the same sample size as the original dataset is
generated by randomly sampling and replacing individuals from the original dataset. For
every new dataset model parameters are determined and the variance of all parameter es-
timates can be calculated, assuming normally distributed parameters. The square route of
the variance is equal to the absolute standard error and thus, the RSE can be calculated
according to equation 4.9.
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4.1.5.3 Graphical methods
Graphical analysis can be used to visually assess the goodness of fit (GOF) and to detect
model misspecifications. During model development the following GOF plots have been
routinely generated using the SAS® software version 9.461:
• Measured observations versus population or individual predictions
• Weighted residuals versus population or individual predictions
• Weighted residuals versus time or time after dose
Weighted residuals are the weighted differences between measured observations and pop-
ulation or individual predictions, respectively. Using the FOCE+I method, the estimation
of conditional weighted residuals is possible, which results in more meaningful statements
about error model62. Ideally all points should be scattered closely, randomly and uniformly
around the line of identity for observations versus population or individual predictions
plots and around the zero line for residual plots.
4.1.5.4 Visual predictive check
The visual predictive check (VPC) is a simulation based tool to graphically evaluate the
predictive power of a model by assessing the accordance of model predictions with obser-
vations63,64. Based on the final model and under original study design sufficiently high
numbers of simulations (≥ 500) were performed. The subsequently calculated 90% predic-
tion interval of the simulated values is then compared to observed data, where the simu-
lated median should reflect the median of the observations. The variability is accurately
reflected by the model when 5% of observations are below and above the 5th and 95th per-
centile, respectively.
4.1.6 Simulations
4.1.6.1 Deterministic simulations
Deterministic simulations consider only the structural parameters of a model whereby the
variability is neglected. Investigating the typical PK and PD profiles can be helpful to ex-
plore the influence of covariates on the PK and PD and to gain insights into the structural
model47.
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4.1.6.2 Stochastic simulations
For stochastic simulations all sources of variability are considered and thus the predicted
model responses (e.g. plasma concentration or tumor growth) represent the reality more ac-
curately and reveal the range of the expected outcome. By randomly sampling sets of model
parameters from the multivariate distribution and subsequent computation of correspond-
ing PK and PD profiles the variability within a population is included. Since stochastic
simulations are the method of choice when several dose regimens are investigated for their
safety and efficacy outcome and suggestions for dose-optimization need to be derived, they
were applied for simulation analysis within this thesis. Stochastic simulations can be fur-
ther used for internal model validation (VPC, section 4.1.5.4).
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5 Results
5.1 Publication I: A generic viral dynamic model to
systematically characterize the interaction between
oncolytic virus kinetics and tumor growth
(doi: 10.1016/j.ejps.2016.11.003)
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5.2 Publication II: A comprehensive
pharmacokinetic/pharmacodynamics analysis of the novel
IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo
and in silico modeling techniques
(doi:10.1007/s00280-016-3049-z)
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5.3 Publication III: An allometric
pharmacokinetic/pharmacodynamics model for BI 893923,
a novel IGF-1 receptor inhibitor
(doi:10.1007/s00280-017-3252-6)
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Currently, many new innovative cancer therapeutics are under investigation, such as self-
replicating oncolytic viruses and small molecule TKIs, which rise hope for an improved tu-
mor therapy and eventually a cure. However, translation of efficacy and safety from in vitro
to in vivo and then to clinical trials remains difficult with a low rate of success, partly due
to bad preclinical experiment design but also due to differences in interspecies pharmacol-
ogy and pharmacokinetics40,41. Thus, there is an urgent need to foster early drug devel-
opment and to evolve new strategies for an improved translational research. Since many
studies fail to adequately relate anti-tumor response to required human drug exposure41,
it is believed that the application of pharmacometric modeling in preclinical drug devel-
opment could considerably improve efficiency and success of drug research by enabling a
sophisticated extrapolation of animal PK and PD to human under consideration of inter-
species differences42. Therefore, translational pharmacometric modeling provides a solid
support to cancer drug development when it is applied in early stage development65,66,
which was demonstrated by the examples of oncolytic viruses and the TKI BI 893923 within
this thesis.
For the three OVs NDV, RV and PV a generic OV model with a joint structure was devel-
oped which describes at the same time tumor growth and virus replication considering the
complex bi-directional tumor-virus interaction. The developed virus dynamics model can
be expanded to other OVs and tumor cell lines beyond the ones tested here and could be
further universally employed to cross-characterize various virus-tumor relations. The virus
dynamics model was successfully used to simulate the long-term tumor-virus interrelation
and to predict tumor reoccurrence for different dosing scenarios. A treatment rating score
was developed, which enabled a preselection of the most promising oncolytic virus within
the optimal dosing regimen for the design of in vivo experiments. In the future the model
can be further utilized to characterize in vitro tumor growth kinetics for tumor cells ob-
tained from patient biopsies to predict the most promising virus strain and dosing regimen
for the individual patient.
For the novel IGF1R/INSR TKI BI 893923 a PK/PD model was developed, which success-
fully described the relationship between BI 893923 plasma concentration, pIGF1R biomarker
modulation as well as resulting tumor growth inhibition and blood glucose levels in mice.
The model was used to simulate different dosing regimens with the result of an improved
safety window with respect to hyperglycemia and increased anti-tumor efficacy for dosing
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every 8 hours compared to once-daily dosing. The PK/PD model successfully supported
the preclinical process and dose optimization in mice and could prospectively be employed
for comparison and evaluation of different IGF1R/INSR TKIs.
For accurate predictions of the human therapeutic dose the BI 893923 PK/PD model was
successfully scaled across mouse, rat, dog, minipig and monkey by allometric principles
and extrapolated to human. External predictions of monkey PK and blood glucose, as
surrogate PD endpoint, confirmed the transferability of the model across various species
and supported the reliability of the human predictions. To broaden the therapeutic win-
dow in human with increased anti-tumor efficacy and reduced duration of hyperglycemia,
various dosing schedules were simulated and a comprehensive risk-benefit analysis was
conducted. Based on the net clinical benefit for each schedule an optimal human dose of
2750 mg BI 893923 every 8 hours was predicted. The here presented allometric PK/PD
model successfully supported the transferability of safety and efficacy at the preclinical-
clinical interface and thus substantially impacted the successful development of a new in-
novate anti-cancer drug. In the future, the model could be used to evaluate other
IGF1R/INSR TKI and to test combination therapies of BI 893923 with other anticancer
drugs such as inhibitors of the epidermal growth factor receptor (EGFR) or MEK as well
as conventional cytotoxic agents67–69. To further optimize the metabolic tolerability, combi-
nations with anti-diabetic drugs such as metformin could be performed70,71 and the model
could be applied to other anti-cancer drugs associated with hyperglycemia such as PI3K-
AktmTOR pathway inhibitors72.
In summary, the projects within this thesis demonstrated the successful application of phar-
macometric modeling in preclinical oncolytic drug development. Utilizing information and
data at different stages of the drug discovery process enabled the development and applica-
tion of predictive models to direct future experiment design and decision making. As basis
for translational research, pharmacometric modeling supported the transferability of drug
safety and efficacy based on rational, data driven suggestions and provided the foundation
for dose-optimization.
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Despite many innovative anti-cancer drugs in the pipeline, the attrition rate for anti-tumor
drugs is high due to a lack of predictability of efficacy and safety from in vitro settings
to animal models and at the preclinical-clinical interphase. In this thesis pharmacometric
modeling was applied to support early cancer drug development exemplary for the con-
cepts of oncolytic viruses (OV) and the tyrosine kinase inhibitor (TKI) BI 893923. For OV
therapy a understanding of the bi-directional tumor-virus interaction is essential. Thus, a
generic viral dynamic model was developed based on in vitro data from Newcastle disease
virus, reovirus and parvovirus for the treatment of U87 glioblastoma cells, which simulta-
neously describes tumor growth and virus kinetics. The model was used for a depiction
of virus efficacy and selection of optimal dose regimens. BI 893923 is a novel TKI of the
insulin-like growth factor 1 receptor (IGF1R) and insulin receptor (INSR) with promising
anti-tumor efficacy. Since for other IGF1R/INSR inhibitors dose-limiting hyperglycemia
was reported, a mouse PK/PD model was developed, relating BI 893923 plasma concen-
tration to biomarker modification and tumor growth as well as blood glucose to balance
anti-tumor efficacy with the risk of hyperglycemia. The model was scaled to human by al-
lometric principles using data from mouse, rat, dog, minipig and monkey and a risk-benefit
analysis was conducted to determine the optimal safe and efficient human dose.
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8 Zusammenfassung
Trotz intensiver Forschung in der Onkologie ist die Zahl neuer Zulassungen gering, da
die Übertragbarkeit von Wirksamkeit und Sicherheit von in vitro Tests auf Tiermodelle
und an der präklinisch-klinischen Schnittstelle nur ungenügend ist. Um die Entwicklung
zu unterstützen, wurden in dieser Arbeit am Beispiel von onkolytischen Viren (OV) und
des Tyrosinkinaseinhibitors (TKI) BI 893923 pharmakometrische Modelle entwickelt. Für
die Therapie mit OV ist ein Verständnis der wechselseitigen Tumor-Virus-Beziehung es-
sentiell. Daher wurde basierend auf in vitro Newcastle disease-, Reo-und Parvovirusdaten
zur Behandlung von U87 Glioblastomzellen ein generisches Virus-Dynamik-Modell entwi-
ckelt, welches simultan Tumorwachstum und Viruskinetik beschreibt. Das Modell wurde
zur Bestimmung von Viruseffizienz und optimaler Dosierungsregime genutzt. BI 893923
ist ein neuer TKI des Insulin-like Growth Faktor 1 Rezeptors (IGF1R) und Insulin Rezep-
tors (INSR). Da für andere IGF1R/INSR TKIs dosislimitierende Hyperglykämien berichtet
wurden, wurde ein Maus PK/PD Model entwickelt, welches die BI 893923 Plasmakonzen-
tration, Biomarkermodifikation, das Tumorwachstum und die Blutglukose beschreibt, um
die antitumorale Wirksamkeit gegen das Hyperglykämierisiko abzuwägen. Es wurden Da-
ten von Maus, Ratte, Hund, Minischwein und Affe genutzt um das Modell allometrisch auf
den Menschen zu skalieren und es wurde eine Risiko-Nutzen-Analyse durchgeführt, um
eine sichere und wirksame humane Dosis zu bestimmen.
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Supplemental Material to: 
A generic viral dynamic model to systematically characterize the interaction between oncolytic virus 
kinetics and tumor growth 
 
Model Equations: 
𝑑𝑇𝑈(𝑡)
𝑑𝑡
= 𝐺𝑟 ∙ 𝑇𝑈(𝑡) ∙ 𝑠𝑡𝑎𝑟𝑡 − 𝑇𝑑 ∙ 𝑇𝑈(𝑡)  −  𝛽 ∙ 𝑇𝑈(𝑡) ∙ 𝑂𝑉(𝑡)    Eq.(A.1) 
𝑑𝑇𝐼(𝑡)
𝑑𝑡
=  𝛽 ∙ 𝑇𝑈(𝑡) ∙ 𝑂𝑉(𝑡) −  𝛿 ∙ 𝑇𝐼(𝑡)        Eq.(A.2) 
𝑑𝑂𝑉(𝑡)
𝑑𝑡
=  𝜌 ∙ 𝑇𝐼(𝑡) − 𝐶𝐿 ∙ 𝑂𝑉(𝑡)        Eq.(A.3) 
With start = 0 if Time <= LAG and start=1 if Time > LAG 
and  𝛿 =
𝐷𝑚𝑎𝑥·𝑂𝑉
𝑁
𝐷𝐶50
𝑁+𝑂𝑉𝑁
          Eq.(A.4) 
The initial condition at time zero for each population is defined as follows: 
𝑇𝑈(0) = 10000 
𝑇𝐼(0) = 0 
𝑂𝑉(0) = 0 
In the above equations, TU are the uninfected tumor cells, TI infected tumor cells and OV the oncolytic 
virus. Gr is the growth rate and Td the death rate of uninfected cells, β denotes the infection rate and 
δ the infected cell death rate. δ is calculated by a sigmoidal Emax-model, where Dmax denotes the 
maximum death rate, DC50 the virus titer for a half-maximum death rate and N the hill factor. ρ 
represent the release rate for new virions and CL the rate for virus clearance. LAG denotes the lag-time 
after which uninfected cells start to grow. Tumor cells were infected with OVs 24 h after seeding.   
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Reproductive ratio R0: 
𝑅0 =  
𝛽 ∙ 𝐺𝑟 ∙ 𝜌
𝛿 ∙ 𝑇𝑑 ∙ 𝐶𝑙
 
Since  
𝐺𝑟
𝑇𝑑
 is the same for all the viruses the constant can be canceled out, leading to  
𝑅0 =  
𝛽 ∙ 𝜌
𝛿 ∙ 𝐶𝑙
 
with 𝛿 =
𝐷𝑚𝑎𝑥·𝑂𝑉
𝑁
𝐷𝐶50
𝑁+𝑂𝑉𝑁
 
As δ is changing over time because it depends on the virus titer at a given time, the reproductive ratio 
R0 for a virus is also changing over time and needs to be calculated for every time point of interest.  
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Supplementary Figure A.1: A) Measured U87 glioblastoma cell growth up to 120 h after infection.  
B) Measured virus titer up to 120h after infection. cc, control group with 0 cp/c virus. 
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Supplementary Figure A.2: Combination of NDV treatment with a cytotoxic compound that induces 
(A) 30% or (B) 60% tumor cell growth inhibition with start of treatment at tumor nadir. Additional 
cytotoxic therapy starting at virus nadir with C) 30% and D) 60% growth inhibition. Arrows indicate 
start of chemotherapy. 
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Supplementary Table A.1: Treatment rating Score and EraScore for combination of NDV with a 
hypothetical cytotoxic compound of 30 or 60% growth inhibition, starting chemotherapy at tumor 
nadir or virus nadir. 
Growth 
inhibition started 
at 
% 
Inhibition 
Dose [cp/c] Score EraScore 
Tumor 
Eradication 
Tumor nadir 30 1 0.26 - no 
Tumor nadir 30 5 0.63 - no 
Tumor nadir 30 10 0.89 - no 
Tumor nadir 30 50 1.89 - no 
Tumor nadir 30 100 2.65 - no 
Tumor nadir 60 1 0 0.075 yes 
Tumor nadir 60 5 0 0.077 yes 
Tumor nadir 60 10 0 0.079 yes 
Tumor nadir 60 50 0 0.083 yes 
Tumor nadir 60 100 0 0.085 yes 
Virus nadir 30 1 1.66 - no 
Virus nadir 30 5 3.17 - no 
Virus nadir 30 10 4.29 - no 
Virus nadir 30 50 10.32 - no 
Virus nadir 30 100 17.40 - no 
Virus nadir 60 1 1.61 - no 
Virus nadir 60 5 3.17 - no 
Virus nadir 60 10 4.29 - no 
Virus nadir 60 50 10.32 - no 
Virus nadir 60 100 0 0.139 yes 
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Supplementary Figure A.3: Simulation of tumor cell number (blue lines) and virus titer (violet lines) 
over 10 weeks for continuous weekly dosing with NDV. 
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Supplementary Figure A.4: Simulation of tumor cell number (blue lines) and NDV virus titer (violet 
lines) over 10 weeks for various levels of tumor load A) 5000 seeded cells, B) 15000 seeded cells, C) 
20000 seeded cells. 
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Supplementary Figure A.5: Simulation of tumor cell number (blue lines) and RV virus titer (violet 
lines) over 10 weeks for various levels of tumor load A) 5000 seeded cells, B) 15000 seeded cells, C) 
20000 seeded cells. 
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Supplementary Figure A.6: Simulation of tumor cell number (blue lines) and PV virus titer (violet 
lines) over 10 weeks for various levels of tumor load A) 5000 seeded cells, B) 15000 seeded cells, C) 
20000 seeded cells. 
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10.2 Supporting Information II: A comprehensive
pharmacokinetic/pharmacodynamics analysis of the novel
IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo
and in silico modeling techniques
42
 43 
 
Supplemental Materials to: 
A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR 
inhibitor BI 893923 applying in vitro, in vivo and in silico techniques  
Melanie I. Titze1, Otmar Schaaf2, Marco H. Hofmann2, Michael P. Sanderson2, Stephan K. 
Zahn2, Jens Quant2, Thorsten Lehr1 
1Clinical Pharmacy, Saarland University, Saarbrücken, Germany 
2Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria 
 
 
Online Resource Material 1: Data characterization for PK/PD modelling 
 
Table 1 
 Compressive data characterization for modelling analysis. 
Model Animals Observations Number of values 
below LLOQ* 
Dose 
groups treated control  treated control 
PK 112 0 344 0 25 7 
Biomarker 60 12 60 12 0 4 
Tumor 102 26 452 138 0 5 
Glucose 117 19 312 35 28 7 
* LLOQ: Lower limit of quantification  
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Online Resource Material 2: Model equations 
PK Model: 
𝑑𝐴1(𝑡)
𝑑𝑡
= −𝐾𝐴1 ∙ 𝐴1(𝑡) 
𝑑𝐴2(𝑡)
𝑑𝑡
= −𝐾𝐴2 ∙ 𝐴2(𝑡) ∙ 𝑠𝑡𝑎𝑟𝑡 
𝑑𝐴3(𝑡)
𝑑𝑡
= 𝐾𝐴1 ∙ 𝐴1(𝑡) + 𝐾𝐴2 ∙ 𝐴2(𝑡) − (
𝐶𝐿
𝑉1
) ∙ 𝐴3(𝑡) − (
𝑄
𝑉1
) ∙ 𝐴3(𝑡) + (
𝑄
𝑉2
) ∙ 𝐴4(𝑡) − (
𝑄2
𝑉1
)
∙ 𝐴3(𝑡) + (
𝑄2
𝑉3
) ∙ 𝐴5(𝑡) 
𝑑𝐴4(𝑡)
𝑑𝑡
= (
𝑄
𝑉1
) ∙ 𝐴3(𝑡) − (
𝑄
𝑉2
) ∙ 𝐴4(𝑡) 
𝑑𝐴5(𝑡)
𝑑𝑡
= (
𝑄2
𝑉1
) ∙ 𝐴3(𝑡) − (
𝑄2
𝑉3
) ∙ 𝐴5(𝑡) 
With start = 0 if Time <= Tlag and start=1 if Time > Tlag  
Biomarker/TGI Model: 
𝑑𝐴6(𝑡)
𝑑𝑡
= 𝐾1 ∙ (
𝐴3(𝑡)
𝑉1
) − 𝐾1 ∙ 𝐴6(𝑡) 
𝑑𝐴7(𝑡)
𝑑𝑡
= 𝐾𝑃𝐻𝑂𝑆 ∙ (1 − (
𝐴7(𝑡)
𝐼𝐶50 + 𝐴7(𝑡)
)) − 𝐾𝐷𝐸−𝑃𝐻𝑂𝑆 ∙ 𝐴7(𝑡)  
𝑑𝐴8(𝑡)
𝑑𝑡
= 𝐾2 ∙ (
𝐴7(𝑡)
𝐵𝑎𝑠𝑒
) − 𝐾2 ∙ 𝐴8(𝑡) 
𝑑𝐴9(𝑡)
𝑑𝑡
= 𝐾2 ∙ 𝐴8(𝑡) − 𝐾2 ∙ 𝐴9(𝑡) 
𝑑𝐴10(𝑡)
𝑑𝑡
=  
𝜆0𝑇 ∙ 𝐴10(𝑡)
[1 + (
𝜆0𝑇
𝜆1𝑇
∙ 𝐴10(𝑡))
𝜓
]
1
𝜓
 
With: 
𝜆0𝑇 = 𝜆0 ∙
𝐴7(𝑡)
𝐵𝑎𝑠𝑒
∙ 𝐴8(𝑡) ∙ 𝐴9(𝑡) 
𝜆1𝑇 = 𝜆1 ∙
𝐴7(𝑡)
𝐵𝑎𝑠𝑒
∙ 𝐴8(𝑡) ∙ 𝐴9(𝑡) 
ψ=20 
𝐾𝑃𝐻𝑂𝑆 = 𝐾𝐷𝐸−𝑃𝐻𝑂𝑆 ∙ 𝐵𝑎𝑠𝑒 
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Glucose Model: 
𝑑𝐴11(𝑡)
𝑑𝑡
= 𝐾𝑆𝑌𝑁 ∙ (1 + 𝐴12(𝑡)) − 𝐾𝐷𝐼𝑆𝑃 ∙ 𝐴11(𝑡) ∙
(
 1 − (
𝐼𝑚𝑎𝑥𝐺𝑙𝑢𝑐 ∙
𝐴3(𝑡)
𝑉1
𝐼𝐶50𝐺𝑙𝑢𝑐 +
𝐴3(𝑡)
𝑉1
)
)
   
𝑑𝐴12(𝑡)
𝑑𝑡
=  − (
𝑄3
𝑉12
) ∙ 𝐴12(𝑡) − (
𝑄4
𝑉12
) ∙ 𝐴12(𝑡) + (
𝑄4
𝑉13
) ∙ 𝐴13(𝑡) 
𝑑𝐴13(𝑡)
𝑑𝑡
=  (
𝑄4
𝑉12
) ∙ 𝐴12(𝑡) − (
𝑄4
𝑉13
) ∙ 𝐴13(𝑡) 
With 𝐾𝑆𝑌𝑁 = 𝐾𝐷𝐼𝑆𝑃 ∙ 𝐵𝐿𝐺𝑙𝑢𝑐    
 
The initial conditions at time zero for each compartment are defined as follows: 
𝐴1(0) = 𝐷𝑜𝑠𝑒 ∙ 𝐹1 
𝐴2(0) = 𝐷𝑜𝑠𝑒 ∙ 𝐹2 
𝐴3(0) = 𝐴4(0) = 𝐴5(0) = 0 
𝐴6(0) = 0 
𝐴7(0) = 𝐵𝑎𝑠𝑒 
𝐴8(0) = 𝐴9(0) = 1  
𝐴10(0) = 𝐵𝐿 
𝐴11(0) = 𝐵𝐿𝐺𝑙𝑢𝑐 
𝐴12(0) = 𝑃𝑙𝑎𝑐𝑒𝑏𝑜 
𝐴13(0) = 0 
With 𝐹1 = (1 − 𝐹𝐹2) ∙ 𝐵𝑉𝑡𝑜𝑡 and 𝐹2 = 𝐹𝐹2 ∙ 𝐵𝑉𝑡𝑜𝑡 
 
In the above equations, A1 and A2 represent the fast and slow absorption compartments, 
respectively and A3 the central PK compartment. A4 and A5 reflect the peripheral 
compartments. A6 denotes the effect compartment and A7 the pIGF1R biomarker 
compartment. The biomarker transit compartments are reflected by A8 and A9 and the tumor 
compartment is represented by A10. A11 reflects the glucose compartment and A12 the 
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central placebo and A13 peripheral placebo compartment. The Placebo PK parameters were 
scaled to mouse based on published human parameters [25].   
Online Resource Material 3: Goodness-of-fit plots
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Fig. 1 Observed vs population predicted (left panels) and individual predicted (right panels) 
A) BI 893923 plasma concentrations, B) tumor pIGF1R levels, C) tumor volumes, D) blood 
glucose concentrations.  
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Online Resource Material 4: Visual predictive checks  
 
Fig. 1 Visual predictive check for BI 893923 plasma concentration based on 500 simulations: 
Observed BI 893923 plasma concentration (black diamonds) is compared to median (dashed 
line) and 90% confidence interval (shaded area) of model predicted concentration.   
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Fig. 2 Visual predictive check for biomarker based on 500 simulations: Observed pIGF1R level 
(black diamonds) is compared to median (dashed line) and 90% confidence interval (shaded 
area) of model predicted pIGF1R level.   
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Fig. 3 Visual predictive check for tumor growth based on 500 simulations: Observed tumor 
volume (black diamonds) is compared to median (dashed line) and 90% confidence interval 
(shaded area) of model predicted tumor volume.   
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Fig. 4 Visual predictive check for blood glucose based on 500 simulations: Observed blood 
glucose (black diamonds) is compared to median (dashed line) and 90% confidence interval 
(shaded area) of model predicted blood glucose.   
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Online Resource 1: Data characterization for allometric PK modelling 
  
Number of 
Animals 
Number of Observations Dose [mg/kg] 
i.v.  p.o.  i.v.  p.o.  i.v.  p.o.  
> LLOQ < LLOQ > LLOQ < LLOQ 
Mouse 6 9 30 0 32 13 10 20, 60 
Rat 3 21 21 3 147 0 5 15, 20, 30, 60, 120 
Dog 3 15 24 3 125 10 3 1, 3, 9, 18, 36 
Minipig 3 0 25 2 0 0 3 - 
Monkey 3 3 26 1 27 0 3 18 
LLOQ: Lower limit of quantitation 
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Online Resource 2: Individual weighted residuals (IWRES) versus population predictions (left panels) 
and versus time after dose (left panels) for BI 893923 plasma concentration. 
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Online Resource 3: Visual predictive checks for allometric PK model 
 
Fig. 1 VPC for mice based on 1000 simulations. Observed BI 893923 plasma concentration (black 
diamond) is compared to median (solid line) and 90% confidence interval (shaded area) of model 
predicted concentration.  
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Fig. 2 VPC for rats based on 1000 simulations. Observed BI 893923 plasma concentration (black 
diamond) is compared to median (solid line) and 90% confidence interval (shaded area) of model 
predicted concentration.  
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Fig. 3 VPC for dogs based on 1000 simulations. Observed BI 893923 plasma concentration (black 
diamond) is compared to median (solid line) and 90% confidence interval (shaded area) of model 
predicted concentration.  
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Fig. 4 VPC for minipigs based on 1000 simulations. Observed BI 893923 plasma concentration (black 
diamond) is compared to median (solid line) and 90% confidence interval (shaded area) of model 
predicted concentration.  
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Fig. 5 VPC for monkeys based on 1000 simulations. Observed BI 893923 plasma concentration (black 
diamond) is compared to median (solid line) and 90% confidence interval (shaded area) of model 
predicted concentration.  
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Online Resource 4: Data characterization for allometric glucose modelling 
  
Number of 
Animals 
Number of 
Observations 
Dose [mg/kg] 
i.v.  p.o.  i.v.  p.o.  i.v.  p.o.  
Mouse - 136 - 347 - 0, 15, 20, 30, 40, 60, 120 
Rat - 24 - 192   15, 20, 30, 60, 120 
Dog 3 18 30 180 3 0, 1, 3, 9, 18, 36 
Minipig 3 12 30 120 3 0, 4.5, 9, 18 
Monkey 3 6 30 60 3 0, 18 
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Online Resource 5: Individual weighted residuals (IWRES) versus population predictions (left panels) 
and versus time after dose (left panels) for blood glucose.  
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Online Resource 6: Visual predictive checks for allometric PK/PD model 
  
Fig. 1 VPC for mice based on 1000 simulations. Observed blood glucose (black diamond) is compared 
to median (solid line) and 90% confidence interval (shaded area) of model predicted blood glucose.   
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Fig. 2 VPC for rats based on 1000 simulations. Observed blood glucose (black diamond) is compared to 
median (solid line) and 90% confidence interval (shaded area) of model predicted blood glucose.  
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Fig. 3 VPC for dogs based on 1000 simulations. Observed blood glucose (black diamond) is compared 
to median (solid line) and 90% confidence interval (shaded area) of model predicted blood glucose.  
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Fig. 4 VPC for minipigs based on 1000 simulations. Observed blood glucose (black diamond) is 
compared to median (solid line) and 90% confidence interval (shaded area) of model predicted blood 
glucose.  
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Fig. 5 VPC for monkeys based on 1000 simulations. Observed blood glucose (black diamond) is 
compared to median (solid line) and 90% confidence interval (shaded area) of model predicted blood 
glucose.  
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Online Resource 7: Model control stream 
 
$PROBLEM allometric scaling of PK/PD 
 
$INPUT SPECIES ID DAY TIME TAD AMT DOSE DV MDV EVID DGR CMT LLOQ BLQ BW BRAIN 
FLAG 
$SUBROUTINES ADVAN6  
 
$MODEL 
NCOMPS = 13 
COMP = (DEPOT1)          ; Depot 1  
COMP = (DEPOT2)          ; Depot 2 
COMP = (CENTRAL)         ; Central PK comp. 
COMP = (PERI1)           ; Peripheral PK comp. 1 
COMP = (PERI2)           ; Peripheral PK comp. 2 
COMP = (BIOM)            ; Biomarker 
COMP = (EFFECT)          ; Biophase  
COMP = (TUMOR)           ; Tumor 
COMP = (TRANS1)          ; Biomarker transit comp. 1 
COMP = (TRANS2)          ; Biomarker transit comp. 1 
COMP = (GLUCOSE)         ; Glucose comp. 
COMP = (PLAC_C)          ; Central Placebo comp. 
COMP = (PLAC_P)          ; Peripheral Placebo comp; 
 
 
$PK 
;PK MODEL 
;body and brain weight [g] -> convert to kg 
CL    = THETA(1) *(BW/1000)**THETA(7)*(BRAIN/1000)**THETA(13) *EXP(ETA(3)) 
V3    = THETA(2) *(BW/1000)**THETA(8) 
Q4    = THETA(3) *(BW/1000)**THETA(9) 
V4    = THETA(4) *(BW/1000)**THETA(10) 
Q5    = THETA(5) *(BW/1000)**THETA(11) 
V5    = THETA(6) *(BW/1000)**THETA(12) 
 
;oral parameters 
KA1   = THETA(14) *(BW/1000)**THETA(15) 
KA2   = THETA(16) *(BW/1000)**THETA(17) *EXP(ETA(4)) 
ALAG2 = THETA(18) *(BW/1000)**THETA(19) 
F1    = THETA(20) *(BW/1000)**THETA(21) *EXP(ETA(1)) 
F2    = THETA(22) *(BW/1000)**THETA(23) *EXP(ETA(2)) 
FTOT  = F1+F2            ; total bioavailability 
 
K34   = Q4/V3 
K43   = Q4/V4 
K35   = Q5/V3 
K53   = Q5/V5 
KE    = CL/V3 
S3    = V3 
 
; BIOMARKER 
BWR   = (BW/1000)/0.02       ; body weight ratio = (BW species)/(mean BW mouse) 
 
KDEPHOS = THETA(24) * BWR**(-0.25)      ; IGF1R dephosphorylation rate 
IC50    = THETA(25) 
BMNUL   = THETA(26)            ; baseline level of pIGF1R 
A_0(6)  = BMNUL             
KPHOS   = KDEPHOS * BMNUL               ; IGF1R phosphorylation rate 
K1      = THETA(27) *(BW/1000)**0.222   ; rate const. for distribution in tumor 
         ; 0.222 is the mean of KA1 and KA2 exponents  
              
; TUMOR 
L0_1   = THETA(28) * BWR**(-0.25) * EXP(ETA(5))  ; exponential growth rate 
L1_1   = THETA(29) * BWR**(-0.25) * EXP(ETA(6))  ; linear growth rate 
Z      = 20 
BASE   = THETA(30)                                ; tumor volume baseline 
A_0(8) = BASE  
 
K2     = THETA(31) *(BW/1000)**0.222 * EXP(ETA(7)); transit rate for biomarker   
                                                  ; inhibition  
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                                                  ; 0.222 is the mean of KA1                  
                                                  ; and KA2 exponents 
A_0(9) = 1   ; baseline transit 1 
A_0(10)= 1   ; baseline transit 2 
; GLUCOSE 
KDISP  = THETA(32) * BWR**(THETA(36))            ; glucose disposal rate 
 
;blood glucose baselines [mMol/l] 
IF(SPECIES.EQ.1) BL = THETA(33) * EXP(ETA(8))   ; MOUSE 
IF(SPECIES.EQ.2) BL = THETA(34) * EXP(ETA(8))   ; RAT 
IF(SPECIES.EQ.3) BL = THETA(35) * EXP(ETA(8))   ; DOG 
IF(SPECIES.EQ.4) BL = THETA(36) * EXP(ETA(8))   ; MONKEY 
IF(SPECIES.EQ.5) BL = THETA(37) * EXP(ETA(8))   ; PIG 
A_0(11)= BL 
 
KSYN   = KDISP * BL                             ; glucose synthesis rate 
EMAX   = THETA(38) 
EC50   = THETA(39) * EXP(ETA(9)) 
 
;PLACEBO MODEL 
F13    = THETA(40) * BWR**(THETA(41))            ; placebo effect 
 
;values from Derendorf et al. J Clin Pharmacol 1991;31:473–6 
V7     = 429.44  * ((BW/1000)/74)**0.75 
V8     = 348.3   * ((BW/1000)/74)**0.75 
CL7    = 356.57  * ((BW/1000)/74)**0.75 
CL8    = 2445.17 * ((BW/1000)/74)**0.75 
 
K70    = CL7/V7 
K78    = CL8/V7 
K87    = CL8/V8 
 
$DES 
C3  = A(3)/V3                ; concentration central PK compartment 
CE  = A(7)                   ; effect compartment  
 
EFF = CE/(IC50 + CE)         ; drug effect on biomarker 
INH = A(6)/BMNUL             ; direct tumor inhibition  
SUM = INH * A(9) * A(10)     ; time-delayed tumor inhibition  
 
L1 = L1_1 * SUM              ; decreased linear growth rate 
L0 = L0_1 * SUM              ; decreased exponential growth rate 
 
EFF2 = (EMAX*C3)/(EC50+C3)   ; drug effect on glucose 
PLAC = A(13)                 ; placebo effect 
 
; PK 
DADT(1)  = -KA1*A(1)  
DADT(2)  = -KA2*A(2) 
DADT(3)  =  KA1*A(1)+KA2*A(2)-KE*A(3)-K34*A(3)+K43*A(4)-K35*A(3)+K53*A(5) 
DADT(4)  =                            K34*A(3)-K43*A(4) 
DADT(5)  =                                              K35*A(3)-K53*A(5) 
; BIOMARKER 
DADT(6)  = KPHOS * (1-EFF) - KDEPHOS*A(6) 
DADT(7)  = K1*C3 - K1*A(7) 
; TUMOR 
DADT(8)  = (L0*A(8))/((1+((L0/L1)*A(8))**Z)**(1/Z)) 
DADT(9)  = K2*INH - K2*A(9) 
DADT(10) = K2*A(9) - K2*A(10) 
; GLUCOSE 
DADT(11) = KSYN * (1+PLAC) - KDISP *A(11) * (1-EFF2) 
DADT(12) = -K78*A(12) + K87*A(13) - K70*A(12) 
DADT(13) =  K78*A(12) - K87*A(13) 
 
 
$ERROR 
IPRED = A(3)/V3 
IF(CMT.EQ.6)  IPRED = A(6) 
IF(CMT.EQ.8)  IPRED = A(8) 
IF(CMT.EQ.11) IPRED = A(11) 
DEL = 0 
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IF(IPRED.EQ.0) DEL = 0.0001 
W = IPRED 
IRES  = DV - IPRED 
IWRES = IRES/(W+DEL) 
Y = IPRED + W*EPS(1) + EPS(2)  
IF(CMT.EQ.6)  Y = IPRED + W*EPS(3) 
IF(CMT.EQ.8)  Y = IPRED + W*EPS(4) + EPS(5) 
IF(CMT.EQ.11) Y = IPRED + W*EPS(6) 
Online Resource 8: Maximum achievable human net clinical benefit with associated tumor growth 
inhibition (TGI) and duration of hyperglycemia within one day (THG) for different dosing regiments after 
90 days of daily dosing 
Regiment Daily Dose [mg] max. NCB TGI [%] THG [h] 
SD 5000 66.4 73.9 7.5 
BID 6 h 5000 80 87.2 7.2 
BID 9 h 5000 82.6 89.6 7 
BID 12 h 5000 82.9 89.9 7 
TID 2750 90.4 90.4 0 
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Online Resource 9: Sensitivity analysis for BI 893923 plasma concentration (Fig. 1), pIGF1R modulation 
(Fig. 2), tumor growth inhibition (Fig. 3) and blood glucose level (Fig. 4) in humans after single oral dose 
of 2000 mg. Every parameter was changed in a range of 0.2 x parameter to 5 x parameter.  
  
Fig. 1 BI 893923 plasma concentration   Fig. 2 pIGF1R inhibition 
  
Fig. 3 Tumor growth inhibition     Fig. 4 Blood Glucose 
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For maximum pIGF1R inhibition a decrease of the receptor dephosphorylation rate leads to a markedly 
reduction in pIGF1R inhibition whereas an increase of the parameter results in less increased receptor 
inhibition, since already more than 90% of receptor are inhibited with the baseline parameter value. 
Despite to PK parameters, tumor growth inhibition was most sensitive to the concentration in the 
biophase for half-maximum phosphorylation inhibition of IGF1R (IC50) and to rates for distribution in 
the tumor (K1) and transit of biomarker inhibition (K2). Interestingly, changes in tumor growth rates 
have no significant impact on the tumor growth inhibition indicating that BI 893923 would affect both 
fast and slow growing tumors. The level of hyperglycemia was effected most by plasma concentration 
for half-maximum glucose disposal inhibition (IC50Gluc), the maximum inhibition of glucose disposal 
inhibition (ImaxGluc) and the glucose disposal rate (KDISP).  
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Online Resource 10: Sensitivity analysis on input data for BI 893923 plasma concentration (Fig. 1), 
pIGF1R modulation (Fig. 2), tumor growth inhibition (Fig. 3) and blood glucose level (Fig. 4) in humans 
after single oral dose of 2000 mg. The predicted outcome for the exclusion of a certain species is 
compared to prediction based all species. 
 
  
Fig. 1 BI 893923 plasma concentration   Fig. 2 p-IGF1R level as percentage of control  
 
 
 
  
Fig. 3 Tumor volume     Fig. 4 Blood glucose 
 
  
73 
 
Online Resource 11: Simulation of PK/PD relation in human after single oral dose (upper panels) and 
three times daily dosing (lower panels). Based on 1000 simulations the population median (solid line) 
and the 90% prediction intervals are plotted for daily doses of 1000, 2000 and 4000mg.  
  
 
Fig. 1 BI 893923 plasma concentration 
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Fig. 2 phospho-IGF1R level as percentage of control  
 
Fig. 3 Tumor volume 
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Fig. 4 Blood glucose 
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